Knittel J J, Hafner B, Patel D G, Verspohl E J
University of Cincinnati, College of Pharmacy, OH 45267-0004.
Pept Res. 1990 Sep-Oct;3(5):224-7.
The cholecystokinin-tetrapeptide (CCK4) analogs Trp-Pro-Asp-Phe-NH2 (3) and Trp-Pro-Asp-Phe-(4'-NO2)-NH2 (4) were found to be nearly equipotent to cholecystokinin-octapeptide (CCK8) in potentiating glucose-induced insulin secretion from islets of Langerhans isolated from rat pancreas. This stimulatory action was found to be dose-dependent and, in the case of 4, to exhibit a biphasic dose-response curve; i.e., at concentrations greater than 1.0 nM, the stimulating effect of 4 is reversed. These results suggest that conformational restriction of CCK4 and/or modification of the phenylalanine residue could produce more potent analogs capable of stimulating insulin release. Such compounds could have potential therapeutic utility in the treatment of non-insulin-dependent diabetes mellitus (NIDDM).
已发现胆囊收缩素四肽(CCK4)类似物色氨酸-脯氨酸-天冬氨酸-苯丙氨酸-氨基(3)和色氨酸-脯氨酸-天冬氨酸-苯丙氨酸-(4'-硝基)-氨基(4)在增强从大鼠胰腺分离的胰岛中葡萄糖诱导的胰岛素分泌方面,与胆囊收缩素八肽(CCK8)几乎具有同等效力。发现这种刺激作用是剂量依赖性的,并且就化合物4而言,呈现双相剂量反应曲线;即,在浓度大于1.0 nM时,化合物4的刺激作用会逆转。这些结果表明,CCK4的构象限制和/或苯丙氨酸残基的修饰可以产生更有效的能够刺激胰岛素释放的类似物。此类化合物在治疗非胰岛素依赖型糖尿病(NIDDM)方面可能具有潜在的治疗用途。